Drugs / Tyzivumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03776695 | Oct 2018 → Jan 2022 | Zika virus infectious disease | Tychan Pte Ltd. | Withdrawn | No outcome recorded |
| Phase 1 | NCT03443830 | Feb → Sep 2018 | Zika virus infectious disease | Tychan Pte Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tyzivumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03776695 ↗ |
| Modality | Monoclonal antibody | “Tyzivumab, ZIKV monoclonal antibody (mAb), study” NCT03443830 ↗ |
| Route | Intravenous | “Tyzivumab will be administered once through single IV infusion over 30 minutes.” NCT03443830 ↗ |